Ascentage Pharma Group International vs Zai Lab
AAPG and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and ZLAB compare
Zai Lab grew revenue faster over the last twelve months (0.02% versus −41.5% for Ascentage Pharma Group International).
Zai Lab keeps more of each dollar of sales as profit, with a net margin of −44.9% compared with −216% at Ascentage Pharma Group International.
Zai Lab scores higher on the StockData Score (6 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | ZLAB |
|---|---|---|
| Size and price | ||
| Market cap | – | $38.2B |
| Share price | $14.62 | $24.60 |
| Change, 1 year | −55.6% | 12.4% |
| Change, 5 years | – | −70.8% |
| Beta (5Y) | 0.79 | 1.10 |
| Employees | 767 | 1,784 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 86.5× |
| P/B | – | 67.8× |
| FCF yield | – | −0.43% |
| Fair value | – | $4.31 |
| Margin of safety | – | −471% |
| Growth | ||
| Revenue growth (TTM) | −41.5% | 0.02% (better) |
| Revenue growth, 5Y average | – | 56.5% |
| Profitability | ||
| Gross margin | 91.5% (better) | 54.7% |
| Operating margin | – | −63.0% |
| Net margin | −216% | −44.9% (better) |
| FCF margin | −209% | −37.0% (better) |
| Return on equity | −156% | −30.0% (better) |
| Return on invested capital | – | −87.6% |
| Financial health | ||
| Debt / equity | 1.50 | 0.45 (better) |
| Interest coverage | – | −45.2× |
| Current ratio | 1.79 | 2.04 (better) |
| Altman Z-score | – | 46.02 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | 2.8% |
| Held by insiders | 13.0% | 0.67% |
| Insider net buying, 12 months | – | −$10.8M |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- ZLAB stock overview
- ZLAB income statement
- ZLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.